nach oben

Current Hepatology Reports

Erschienen in:

26.10.2020 | Hepatitis B (JK Lim, Section Editor)

Role of Nucleic Acid Polymers and Entry Inhibitors in Functional Cure Strategies for HBV

verfasst von: Sasan Sakiani, Bilal Asif, Alexander Yang, Christopher Koh

Erschienen in: Current Hepatology Reports | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Hepatitis B virus (HBV) infection is one of the most common viral infections worldwide with an estimated 2 billion people exposed to HBV and 240 million with active chronic infection. Despite this, less than 1% of patients with chronic HBV infection receive treatment, and less than 3% of those achieve functional cure with traditional therapies. This review summarizes recent advances in the treatment of chronic HBV utilizing nucleic acid polymers (NAP) and entry inhibitors (EI).

Recent Findings

A recent phase 2 study evaluating the use of NAP following tenofovir and pegylated interferon (PEG-IFN) demonstrated increased rates of functional cure which persisted in 35% of patients after 48 weeks of follow-up. In addition, the EI Myrcludex B has demonstrated HBsAg response in up to 40% of patients when used in combination with PEG-IFN at week 72.

Summary

Functional cure is considered the “holy grail” of treatment, and many new therapies are under investigation for the treatment of chronic HBV. As we work towards functional cure for chronic HBV, NAPs and EIs have shown efficacy in reducing HBV DNA and HBsAg levels and have emerged as potential therapeutic agents that may lead to a functional cure for HBV.

Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva World Heal Organ [Internet]. 2015;March. Available from: https://www.ncbi.nlm.nih.gov/books/NBK305548/. Accessed 20 May 2020.

Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, et al. Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2011;9(1):64–70.PubMed

Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med. 2004;350(11):1118–29.PubMed

Noureddin M, Gish R. Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Curr Gastroenterol Rep. 2014;16:365.PubMed

Koh C, Heller T, Glenn JS. Pathogenesis of and New Therapies for Hepatitis D. Gastroenterology. 2019;156(2):461–476.e1.PubMed

World Health Organization (WHO). Hepatitis B: key facts. WHO. 2019.

Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.PubMed

Lok ASF. Prevention of hepatitis B virus-related hepatocellular carcinoma. In: Gastroenterology. 2004

Halegoua-De Marzio D, Hann HW. Then and now: the progress in hepatitis B treatment over the past 20 years. World J Gastroenterol. 2014;20(2):401–13.PubMedPubMedCentral

10.

Dianzani F, Antonelli G, Capobianchi MR. The biological basis for clinical use of interferon. J Hepatol. 1990;11:S5–S10.PubMed

11.

Wong VWS, Wong GLH, Yan KKL, Chim AML, Chan HY, Tse CH, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;52:S399.

12.

Konerman MA, Lok AS. Interferon treatment for hepatitis B. Clinics Liver Disease. 2016;20:645–65.

13.

Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis b. J Antimicrob Chemother. 2011;66(12):2715-2725

14.

Gish RG, Chang TT, Lai CL, De Man R, Gadano A, Poordad F, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. 2010;17(1):16–22.PubMed

15.

Lok ASF, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-Term Safety of Lamivudine Treatment in Patients with Chronic Hepatitis B. Gastroenterology. 2003;125(6):1714–22.PubMed

16.

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743–51.PubMed

17.

Marcellin P, Heathcote EJ, Buti M, Gane E, De Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359(23):2442–55.PubMed

18.

Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68(4):672–81.PubMed

19.

Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J Viral Hepat. 2005;12(4):333–45.PubMed

20.

Prescott NA, Bram Y, Schwartz RE, David Y. Targeting hepatitis B virus covalently closed circular DNA and hepatitis B virus X protein: recent advances and new approaches. ACS Infect Dis. 2019;5:1657–67.PubMedPubMedCentral

21.

Lucifora J, Protzer U. Attacking hepatitis B virus cccDNA – The holy grail to hepatitis B cure. J Hepatol. 2016;64(1 Supplement):S41–8.PubMed

22.

Block TM, Rawat S, Brosgart CL. Chronic hepatitis B: a wave of new therapies on the horizon. Antivir Res. 2015;121:69–81.PubMed

23.

Eckstein F Phosphorothioates, essential components of therapeutic oligonucleotides. Vol. 24, Nucleic Acid Therapeutics. Mary Ann Liebert Inc.; 2014. p. 374–87.

24.

Noordeen F, Vaillant A, Jilbert AR. Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro. Antimicrob Agents Chemother. 2013;57(11):5291–8.PubMedPubMedCentral

25.

Guzman EM, Cheshenko N, Shende V, Keller MJ, Goyette N, Juteau J-M, et al. Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression. Antivir Ther. 2007;12(8):1147–56.PubMed

26.

Matsumura T, Hu Z, Kato T, Dreux M, Zhang Y-Y, Imamura M, et al. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. YGAST. 2009;137:673–81.

27.

Vaillant A, Juteau J-M, Lu H, Liu S, Lackman-Smith C, Ptak R, et al. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 Core formation downloaded from. Antimicrob Agents Chemother. 2006;50(4):1393–401.PubMedPubMedCentral

28.

Kocisko DA, Vaillant A, Lee KS, Arnold KM, Bertholet N, Race RE, et al. Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrob Agents Chemother. 2006;50(3):1034–44.PubMedPubMedCentral

29.

Schultz U, Grgacic E, Nassal M. Duck hepatitis B virus: an invaluable model system for HBV infection. Adv Virus Res. 2004;63:1–70.PubMed

30.

Guillot C, Martel N, Berby F, Bordes I, Hantz O, Blanchet M, et al. Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes. PLoS One. 2017;12(6):1–15.

31.

Koller E, Vincent TM, Chappell A, De S, Manoharan M, Bennett CF. Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res. 2011;39(11):4795–807.PubMedPubMedCentral

32.

Yang B, Ming X, Cao C, Laing B, Yuan A, Porter MA, et al. High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides. Nucleic Acids Res. 2015;43(4):1987–96.PubMedPubMedCentral

33.

•• Blanchet M, Sinnathamby V, Vaillant A, Labonté P. Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15 cells. Antivir Res. 2019;164:97–105 First proposed NAP mechanism of action during SVP assembly.PubMed

34.

Noordeen F, Vaillant A, Jilbert AR. Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother. 2013;57(11):5299–306.PubMedPubMedCentral

35.

Krieg AM. Immune effects and mechanisms of action of CpG motifs. Vol. 19, Vaccine. Elsevier BV; 2000. p. 618–22.

36.

Noordeen F, Scougall CA, Grosse A, Qiao Q, Ajilian BB, Reaiche-Miller G, et al. Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection. PLoS One. 2015;10(11):e0140909.PubMedPubMedCentral

37.

Roehl I, Seiffert S, Brikh C, Quinet J, Jamard C, Dorfler N, et al. Nucleic acid polymers with accelerated plasma and tissue clearance for chronic hepatitis B therapy. Mol Ther - Nucleic Acids. 2017;8:1–12.PubMedPubMedCentral

38.

• Al-Mahtab M, Bazinet M, Vaillant A. Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg + chronic hepatitis B infection. PLoS One. 2016;11(6):e0156667 First NAP clinical trial showing successful antiviral activity in humans.PubMedPubMedCentral

39.

•• Bazinet M, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy. Gastroenterology. 2020;158(8):2180–94 Largest clinical trial to date investigating NAP in combination therapy with traditional HBV therapies.PubMed

40.

Shekhtman L, Borochov N, Cotler S, Hershkovich L, Uprichard S, Al-Mahtab M, et al. Modeling serum HBsAg, HBV DNA and transaminase kinetics during REP 2139 monotherapy in chronic HBeAg+ HBV infection. J Hepatol. 2018;68:S508.

41.

Lobritz MA, Ratcliff AN, Arts EJ. HIV-1 entry, inhibitors, and resistance. Viruses. 2010;2:1069–105.PubMedPubMedCentral

42.

Fernholz D, Galle PR, Stemler M, Brunetto M, Bonino F, Will H. Infectious hepatitis b virus variant defective in pre-s2 protein expression in a chronic carrier. Virology. 1993;194:137–48.PubMed

43.

•• Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012;1:e00049 Key study that identified NTCP as the receptor for HBV, opening the possibility of a new therapeutic target.PubMedPubMedCentral

44.

Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2014;146(4):1070–83.PubMed

45.

Yan H, Liu Y, Sui J, Li W. NTCP opens the door for hepatitis B virus infection. Antivir Res. 2015;121:24–30.PubMed

46.

Huang H-C, Chen C-C, Chang W-C, Tao M-H, Huang C. Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis. J Virol. 2012;86:9443–53.PubMedPubMedCentral

47.

Zhao K, Liu S, Chen Y, Yao Y, Zhou M, Yuan Y, et al. Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B. Emerg Microbes Infect. 2018;7(1):186.PubMedPubMedCentral

48.

• König A, Döring B, Mohr C, Geipel A, Geyer J, Glebe D. Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes. J Hepatol. 2014;61(4):867–75 Study demonstrating that NTCP can be used as a target for entry inhibitors.PubMed

49.

Fu LL, Liu J, Chen Y, Wang FT, Wen X, Liu HQ, et al. In silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy. Cell Prolif. 2014;47:326–35.PubMed

50.

Serrao E, Xu ZL, Debnath B, Christ F, Debyser Z, Long YQ, et al. Discovery of a novel 5-carbonyl-1H-imidazole-4-carboxamide class of inhibitors of the HIV-1 integrase-LEDGF/p75 interaction. Bioorg Med Chem. 2013;21:5963–72.PubMed

51.

Saso W, Tsukuda S, Ohashi H, Fukano K, Morishita R, Matsunaga S, et al. A new strategy to identify hepatitis B virus entry inhibitors by AlphaScreen technology targeting the envelope-receptor interaction. Biochem Biophys Res Commun. 2018;501(2):374–9.PubMed

52.

Osada H. Introduction of new tools for chemical biology research on microbial metabolites. Bioscience, Biotechnology and Biochemistry. 2010;74(6):1135-1140

53.

Kaneko M, Futamura Y, Tsukuda S, Kondoh Y, Sekine T, Hirano H, et al. Chemical array system, a platform to identify novel hepatitis b virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide. Sci Rep. 2018;8:2769.PubMedPubMedCentral

54.

Passioura T, Suga H. A RaPID way to discover nonstandard macrocyclic peptide modulators of drug targets. Chem Commun. 2017;53(12):1931–40.

55.

Passioura T, Watashi K, Fukano K, Shimura S, Saso W, Morishita R, et al. De Novo Macrocyclic Peptide Inhibitors of Hepatitis B Virus Cellular Entry. Cell Chem Biol. 2018;25(7):906–915.e5.PubMed

56.

Miyakawa K, Matsunaga S, Yamaoka Y, Dairaku M, Fukano K, Kimura H, et al. Development of a cell-based assay to identify hepatitis B virus entry inhibitors targeting the sodium taurocholate cotransporting polypeptide. Oncotarget. 2018;9(34):23681–94.PubMedPubMedCentral

57.

Goh B, Choi J, Kang JA, Park SG, Seo J, Kim TY. Development of a mass spectrometric screening assay for hepatitis B virus entry inhibitors. J Pharm Biomed Anal. 2020;178:112959.PubMed

58.

Shimura S, Watashi K, Fukano K, Peel M, Sluder A, Kawai F, et al. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. J Hepatol. 2017;66:685–92.PubMed

59.

Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S, et al. Cyclosporin a and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology. 2014;59:1726–37.PubMedPubMedCentral

60.

Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, et al. Cyclosporin a inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol. 2014;60:723–31.PubMed

61.

Donkers JM, Zehnder B, Van Westen GJP, Kwakkenbos MJ, Ijzerman AP, Oude Elferink RPJ, et al. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP. Sci Rep. 2017;7(1):15307.PubMedPubMedCentral

62.

Iwamoto M, Watashi K, Tsukuda S, Aly HH, Fukasawa M, Fujimoto A, et al. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. Biochem Biophys Res Commun. 2014;443:808–13.PubMed

63.

Lucifora J, Esser K, Protzer U. Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Antivir Res. 2013;97(2):195–7.PubMed

64.

Abbas Z, Saad M, Asim M, Abbas M, Samejo SA. The effect of twelve weeks of treatment with ezetimibe on HDV RNA level in patients with chronic hepatitis D. Turk J Gastroenterol. 2020;31:136–41.PubMedPubMedCentral

65.

Fukano K, Tsukuda S, Oshima M, Suzuki R, Aizaki H, Ohki M, et al. Troglitazone impedes the oligomerization of sodium taurocholate cotransporting polypeptide and entry of hepatitis B virus into hepatocytes. Front Microbiol. 2019;9:3257.PubMedPubMedCentral

66.

Nio Y, Akahori Y, Okamura H, Watashi K, Wakita T, Hijikata M. Inhibitory effect of fasiglifam on hepatitis B virus infections through suppression of the sodium taurocholate cotransporting polypeptide. Biochem Biophys Res Commun. 2018;501:820–5.PubMed

67.

Blanchet M, Sureau C, Labonté P. Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle. Antivir Res. 2014;106:111–5.PubMed

68.

Ko C, Park WJ, Park S, Kim S, Windisch MP, Ryu WS. The FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide. Antivir Ther. 2015;20:835–42.PubMed

69.

Jun WX, Hu W, Yu ZT, Ying MY, Nan LN, Qi WS. Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na+−dependent taurocholate cotransporting polypeptide activity. Antivir Res. 2015;120:140–6.

70.

Pereira IVA, Buchmann B, Sandmann L, Sprinzl K, Schlaphoff V, Döhner K, et al. Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP). PLoS One. 2015;10(2):e0117152.

71.

Umetsu T, Inoue J, Kogure T, Kakazu E, Ninomiya M, Iwata T, et al. Inhibitory effect of silibinin on hepatitis B virus entry. Biochem Biophys Reports. 2018;14:20–5.

72.

Bruss V, Hagelstein J, Gerhardt E, Galle PR. Myristylation of the large surface protein is required for hepatitis B virus in vitro infectivity. Virology. 1996;218(2):396–9.PubMed

73.

Gripon P, Seyec JLE, Rumin S, Guguen-Guillouzo C. Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology. 1995;213:292–9.PubMed

74.

•• Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol. 2005;79(3):1613–22 Important study that led to Myrcludex B.PubMedPubMedCentral

75.

Schulze A, Schieck A, Ni Y, Mier W, Urban S. Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J Virol. 2010;84:1989–2000.PubMed

76.

Glebe D, Urban S, Knoop EV, Çaǧ N, Krass P, Grün S, et al. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology. 2005;129:234–45.PubMed

77.

Petersen J, Dandri M, Mier W, Lütgehetmann M, Volz T, Von Weizsäcker F, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol. 2008;26(3):335–41.PubMed

78.

Volz T, Allweiss L, ḾBarek MB, Warlich M, Lohse AW, Pollok JM, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013;58(5):861–7.PubMed

79.

Lütgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, Bornscheuer T, et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology. 2012;55:685–94.PubMed

80.

Schieck A, Schulze A, Gähler C, Müller T, Haberkorn U, Alexandrov A, et al. Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts. Hepatology. 2013;58(1):43–53.PubMed

81.

Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol. 2016;65:483–9.PubMed

82.

•• Bogomolov P. A phase 1b/2a randomized, open-label clinical trial of daily Myrcludex B versus entecavir in patients with HBeAg negative chronic hepatitis B [internet]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02881008. Accessed 28 Sept 2020. First human trial showing efficacy in HBV DNA suppression.

83.

Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol. 2016;65:490–8.PubMed

84.

• Wedemeyer H, Bogomolov P, Blank A, Allweiss L, Dandri-Petersen M, Bremer B, et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection. J Hepatol. 2018;68(1):S3 Phase II study demonstrating HBsAg decline and negativation.

85.

Wedemeyer H A Multicenter, open-label, randomized clinical study to assess efficacy and safety of 3 doses of Myrcludex B for 24 weeks in combination with tenofovir compared to tenofovir alone to suppress HBV replication in patients with chronic hepatitis D [Internet]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT03546621. Accessed 28 Sept 2020.

86.

Wedemeyer H, Schöneweis K, Bogomolov PO, Voronkova N, Chulanov V, Stepanova T, et al. GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. J Hepatol. 2019;70(1):e81 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0618827819301410. Accessed 28 Sept 2020.

87.

Wedemeyer H, Schöneweis, Bogomolov PO, Chulanov V, Stepanova T, Viacheslav M, et al. 48 weeks of high dose (10mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection. J Hepatol. 2020;73:S52–3 Available from: https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf. Accessed 28 Sept 2020.

Titel: Role of Nucleic Acid Polymers and Entry Inhibitors in Functional Cure Strategies for HBV
verfasst von: Sasan Sakiani
Bilal Asif
Alexander Yang
Christopher Koh
Publikationsdatum: 26.10.2020
Verlag: Springer US
Erschienen in: Current Hepatology Reports / Ausgabe 4/2020
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-020-00550-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

National and Global Ethnicity Differences in Non-alcoholic Fatty Liver Disease

Exercise as Medicine: The Impact of Exercise Training on Nonalcoholic Fatty Liver Disease

The Role of RNA Interference in Functional Cure Strategies for Chronic Hepatitis B

Genomic Landscape of HCC

Role of Immunomodulators in Functional Cure Strategies for HBV

Current and Emerging Treatments for Non-alcoholic Steatohepatitis